



UNITED STATES PATENT AND TRADEMARK OFFICE

C/C

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/049,608	09/16/2002	Cohava Gelber	3823-4000US2	4734
27123	7590	11/04/2005	EXAMINER	
MORGAN & FINNEGAN, L.L.P. 3 WORLD FINANCIAL CENTER NEW YORK, NY 10281-2101			RAWLINGS, STEPHEN L	
			ART UNIT	PAPER NUMBER
			1643	

DATE MAILED: 11/04/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	10/049,608	GELBER, COHAVA
	Examiner	Art Unit
	Stephen L. Rawlings, Ph.D.	1643

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on ____.
 2a) This action is FINAL. 2b) This action is non-final.
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-44 is/are pending in the application.
 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
 5) Claim(s) ____ is/are allowed.
 6) Claim(s) ____ is/are rejected.
 7) Claim(s) ____ is/are objected to.
 8) Claim(s) 1-44 are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.
 10) The drawing(s) filed on ____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. ____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) Notice of References Cited (PTO-892)
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
 Paper No(s)/Mail Date ____.

4) Interview Summary (PTO-413)
 Paper No(s)/Mail Date. ____.

5) Notice of Informal Patent Application (PTO-152)
 6) Other: ____.

DETAILED ACTION

1. Claims 1-44 are pending in the application and are currently subject to restriction.

Election/Restrictions

2. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-9, 11-13, 18-20, 34-36, and 39-44, drawn to a monoclonal antibody or binding fragment thereof, a hybridoma, a medicament comprising a monoclonal antibody or binding fragment thereof, a medicament or pharmaceutical composition comprising an antibody or binding fragment thereof conjugated to a cytotoxic or detectable moiety, and a method of removing myeloma cells from an isolated cellular sample.

Group II, claim(s) 10, drawn to an anti-idiotypic antibody.

Group III, claim(s) 14-17, drawn to an antigen, which is a glycoprotein.

Group IV, claim(s) 29-33, a method for inhibiting or killing myeloma cells in an isolated cellular sample.

Group V, claim(s) 37, drawn to a method for detecting the presence and extent of ovarian cancer in a patient comprising determining the level of an antigen in a sample of bodily fluid.

Group VI, claim(s) 38, drawn to a method for monitoring the effectiveness of therapy for ovarian cancer comprising determining the level of an antigen in a sample of bodily fluid.

3. The inventions listed as Groups I-VI do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The special technical feature of Group I is making a hybridoma and a monoclonal antibody, or binding fragment thereof, and using the monoclonal antibody or binding fragment to remove myeloma cells from an isolated cellular sample.

The special technical feature of Group II is making an anti-idiotypic antibody.

The special technical feature of Group III is making an antigen, which is a glycoprotein.

The special technical feature of Group IV is inhibiting or killing myeloma cells in an isolated cellular sample by a process comprising exposing a cellular sample to a monoclonal antibody or binding fragment thereof.

The special technical feature of Group V is detecting the presence and extent of ovarian cancer in a patient comprising determining the level of an antigen in a sample of bodily fluid acquired from the patient and correlating the level of the antigen with the presence and extent of ovarian cancer in the patient.

The special technical feature of Group VI is monitoring the effectiveness of therapy for ovarian cancer comprising determining the level of an antigen in a sample of bodily fluid acquired from the patient and correlating the level of the antigen with the effectiveness of therapy for ovarian cancer in the patient.

Accordingly, the inventions of Groups I-VI do not share the same or corresponding special technical feature so as to form a single general inventive concept under PCT Rules 13.1 and 13.2. In addition, PCT Rules 13.1 and 13.2 do not provide for a single general inventive concept to comprise more than the first mentioned product, the first mentioned method for making said product, and the first mentioned method for using said product.


4. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Conclusion

5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Stephen L. Rawlings, Ph.D. whose telephone number is (571) 272-0836. The examiner can normally be reached on Monday-Friday, 8:30AM-5:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Larry Helms, Ph.D. can be reached on (571) 272-0832. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



Stephen L. Rawlings, Ph.D.
Examiner
Art Unit 1643